F. Spyratos

F. Spyratos, S. Romain, H. Magdelenat, 1995, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

Harmonisation of multi-centre real-time reverse-transcribed PCR results of a candidate prognostic marker in breast cancer: an EU-FP6 supported study of members of the EORTC - PathoBiology Group.

A. Sieuwerts, J. Martens, P. Span, 2009, European journal of cancer.

KRAS mutation status in colorectal cancer to predict response to EGFR targeted therapies: the need for a more precise definition

I. Bièche, R. Lidereau, F. Spyratos, 2008, British Journal of Cancer.

Comments on the use of a single or multiple probeset approach for microarray-based analyses of routine molecular markers in breast cancer

I. Bièche, B. Asselain, F. Spyratos, 2012, Breast Cancer Research and Treatment.

Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients

N. Brünner, M. Fernö, J. Foekens, 2003, Thrombosis and Haemostasis.

Luteinizing hormone/human chorionic gonadotropin receptors in breast cancer.

E. Milgrom, F. Spyratos, N. Charnaux, 1997, Cancer research.

Inter-laboratory quality control for hormone-dependent gene expression in human breast tumors using real-time reverse transcription-polymerase chain reaction.

I. Bièche, B. Asselain, V. Bécette, 2004, Endocrine-related cancer.

Summary version of the standards, options and recommendations for nonmetastatic breast cancer (updated January 2001)

R. Gilles, M. Dilhuydy, L. Mauriac, 2003, British Journal of Cancer.

Is Adjuvant Tamoxifen Recommended in Post-Menopausal Node-Negative Breast Cancer Patients with High Estrogen Receptor Values?

F. Spyratos, K. Hacène, F. Turpin, 2000, The International journal of biological markers.

Flow cytometric DNA analysis and Samba computer assisted image analysis in the evaluation of breast carcinoma chemosensitivity

M. Tubiana-Hulin, F. Spyratos, M. Briffod, 1991 .

Re: Prognostic importance of low c-erbB2 expression in breast tumors.

M. Tubiana-Hulin, F. Spyratos, K. Hacène, 1999, Journal of the National Cancer Institute.

Immunoradiometric assay of pro-cathepsin D in breast cancer cytosol: relative prognostic value versus total cathepsin D.

T. Maudelonde, F. Spyratos, H. Rochefort, 1993, European journal of cancer.

Immunocytochemical staining of progesterone receptor in paraffin sections of human breast cancers.

E. Milgrom, F. Spyratos, M. Perrot-Applanat, 1989, The American journal of pathology.

Timing of surgery in breast cancer

T. Powles, F. Spyratos, J. Gazet, 1991, The Lancet.

Multiparametric prognostic evaluation of biological factors in primary breast cancer.

F. Spyratos, S. Romain, V. Le Doussal, 1992, Journal of the National Cancer Institute.

Influence of the extraction procedure on plasminogen activator inhibitor-2 (PAI-2) and urokinase receptor (uPAR) assays in breast cancer tissues

V. Bécette, F. Spyratos, C. Andrieu, 2005, Breast Cancer Research and Treatment.

EORTC Receptor Study Group Report Technical Evaluation of Thymidine Kinase Assay in Cytosols from Breast Cancers

F. Spyratos, S. Romain, S. Deytieux, 1994 .

Technical evaluation of thymidine kinase assay in cytosols from breast cancers. EORTC Receptor Study Group Report.

O. Chinot, F. Spyratos, S. Romain, 1994, European journal of cancer.

Re: Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.

F. Spyratos, K. Hacène, M. Ferrero-Poüs, 2003, Journal of the National Cancer Institute.

Prognostic value of histologic grade nuclear components of Scarff‐Bloom‐Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas

S Friedman, M Brunet, S. Friedman, 1989, Cancer.

pS2 and response to adjuvant hormone therapy in primary breast cancer.

P. Chambon, F. Spyratos, C. Andrieu, 1994, British Journal of Cancer.

[Standardization and quality control in the evaluation of proliferation parameters in T1T2, N0N1, M0 breast cancer: multicentric retrospective study II. DNA-ploidy and S-phase fraction].

M. Bolla, F. Spyratos, S. Romain, 1999, Bulletin du cancer.

Correlation between MIB‐1 and other proliferation markers

F. Spyratos, E. Phillips, V. Le Doussal, 2002, Cancer.

Polymerase chain reaction analysis of parathyroid hormone-related protein gene expression in breast cancer patients and occurrence of bone metastases.

F. Spyratos, A. Jullienne, Z. Bouizar, 1993, Cancer research.

Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.

F. Spyratos, K. Hacène, P. Martin, 1994, British Journal of Cancer.

Immunohistochemical detection of alphalactalbumin in breast lesions.

F. Spyratos, P. Franchimont, V. Le Doussal, 1984, European journal of cancer & clinical oncology.

Breast Cyst Fluid Proteins and Breast Cancer a

F. Spyratos, P. Franchimont, K. Hacène, 1986, Annals of the New York Academy of Sciences.

Cytokeratin analysis of breast and leukemia tumor cell lines by flow cytometry

F. Spyratos, E. Phillips, A. Desplaces, 1989, Biology of the cell.

Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab

I. Bièche, B. Asselain, M. Marty, 2013, British Journal of Cancer.

Profiling of EGFR mRNA and protein expression in 471 breast cancers compared with 10 normal tissues: A candidate biomarker to predict EGFR inhibitor effectiveness

S. Vacher, I. Bièche, R. Lidereau, 2012, International journal of cancer.

Identification of new candidate therapeutic target genes in triple-negative breast cancer.

Rosette Lidereau, Didier Meseure, S. Vacher, 2012, Genes & cancer.

DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and

J. Foekens, J. Nährig, J. Martens, 2007, European journal of cancer.

Thymidine kinase as a proliferative marker: clinical relevance in 1,692 primary breast cancer patients.

B Asselain, P Broët, B. Asselain, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach.

S. Vacher, I. Bièche, S. Tozlu, 2006, Endocrine-related cancer.

A nomogram to predict individual prognosis in node-negative breast carcinoma.

F. Spyratos, S. Romain, C. Mazouni, 2012, European journal of cancer.

Evaluation of breast carcinoma chemosensitivity by flow cytometric DNA analysis and computer assisted image analysis.

F. Spyratos, K. Hacène, M. Briffod, 1992, Cytometry.

Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas.

R. Lidereau, F. Spyratos, C. Theillet, 1986, Proceedings of the National Academy of Sciences of the United States of America.

Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer.

I. Bièche, R. Lidereau, I. Treilleux, 2008, Journal of molecular endocrinology.

Identification of TACC 1 , NOV , and PTTG 1 as new candidate genes associated with endocrine therapy resistance in breast cancer

I. Bièche, R. Lidereau, I. Treilleux, 2009 .

CDO1 Promoter Methylation is a Biomarker for Outcome Prediction of Anthracycline Treated, Estrogen Receptor-Positive, Lymph Node-Positive Breast Cancer Patients

J. Foekens, J. Martens, Jörn Dietrich, 2010, BMC Cancer.

DNA Methylation Markers Predict Outcome in Node-Positive, Estrogen Receptor-Positive Breast Cancer with Adjuvant Anthracycline-Based Chemotherapy

J. Foekens, J. Martens, D. Dietrich, 2009, Clinical Cancer Research.

Fine-needle cytopuncture and flow cytometry in the characterization of human tumors.

F. Spyratos, M. Briffod, 1994, Methods in cell biology.

The Parathyroid Hormone–Related Protein (PTHrP) Gene: Use of Downstream TATA Promotor and PTHrP 1–139 Coding Pathways in Primary Breast Cancers Vary with the Occurrence of Bone Metastasis

F. Spyratos, M. de Vernejoul, Z. Bouizar, 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Prognostic Assessment Of PTK Activity in T1-T2, N0-N1, M0 Breast Cancer: A Multicentric Retrospective Study

M. Bolla, F. Spyratos, E. Chambaz, 2002, Breast Cancer Research and Treatment.

Methylated genes as new cancer biomarkers.

J. Foekens, P. Span, F. Spyratos, 2009, European journal of cancer.

Optimizing flow cytometric DNA ploidy and S-phase fraction as independent prognostic markers for node-negative breast cancer specimens.

G. Clark, P. Bendahl, C. B. Bagwell, 2001, Cytometry.

DNA content and cell cycle analysis by flow cytometry in clinical samples: Application in breast cancer

F. Spyratos, 1993, Biology of the cell.

Prognostic Value of Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA) Content of Human Breast Carcinomas: Correlation with Clinical and Histologic Features and Hormone Receptors

R. Lidereau, F. Spyratos, A. Desplaces, 1986 .

Frequency and genome load of Epstein-Barr virus in 509 breast cancers from different geographical areas

F. Spyratos, J. Seigneurin, M. Buisson, 2001, British Journal of Cancer.

Prognostic factor clustering in breast cancer: biology or chronology?

F. Spyratos, K. Hacène, P. Martin, 1995, European journal of cancer.

Validation of tumor‐associated macrophage ferritin light chain as a prognostic biomarker in node‐negative breast cancer tumors: A multicentric 2004 national PHRC study

M. Campone, F. Spyratos, G. Ricolleau, 2012, International journal of cancer.

Dissemination risk index based on plasminogen activator system components in primary breast cancer.

V. Bécette, F. Spyratos, K. Hacène, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases

L. Xerri, A. Salomon, B. Esterni, 2013, BMC Cancer.

Importance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patients

Jean-Marc Guinebretière, Nicolas Servant, Bernard Asselain, 2011, BMC Cancer.

Prognostic value of uPA and p53 accumulation measured by quantitative biochemical assays in 1245 primary breast cancer patients: a multicentre study

B. Asselain, F. Spyratos, C. Toulas, 1999, British Journal of Cancer.

Tissue Plasminogen Activator in the Cytosol of Breast Tumors: Technical Aspects and Correlations with Commonly Used Prognostic Factors

F. Spyratos, A. Desplaces, K. Hacène, 1985 .

The Lancet: saturday 11 November 1989

T. Maudelonde, F. Spyratos, H. Rochefort, 1989 .

CATHEPSIN D: AN INDEPENDENT PROGNOSTIC FACTOR FOR METASTASIS OF BREAST CANCER

T. Maudelonde, F. Spyratos, H. Rochefort, 1989, The Lancet.

S-phase fraction and DNA ploidy in 633 T1T2 breast cancers: a standardized flow cytometric study.

M. Bolla, F. Spyratos, S. Romain, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Immunocytochemical study with monoclonal antibodies to progesterone receptor in human breast tumors.

E. Milgrom, F. Spyratos, M. Perrot-Applanat, 1987, Cancer research.

Improvement of quality control for steroid receptor measurements: Analysis of distributions in more than 40000 primary breast cancers

F. Spyratos, S. Romain, H. Magdelenat, 2005, Breast Cancer Research and Treatment.

Prolonged tamoxifen treatment increases relapse-free survival for patients with primary breast cancer expressing high levels of VEGF.

F. Spyratos, O. Stål, B. Nordenskjöld, 2010, European journal of cancer.

Limited Prognostic Value of c-erbB-2 Compared to uPA and PAI-1 in Primary Breast Carcinoma

V. Bécette, F. Spyratos, K. Hacène, 2003 .

Limited prognostic value of c-erbB-2 compared to uPA and PAI-1 in primary breast carcinoma.

V. Bécette, F. Spyratos, K. Hacène, 2003, The International journal of biological markers.

Prognostic value of urokinase plasminogen activator in primary breast carcinoma: comparison of two immunoassay methods.

F. Spyratos, C. Bouchet, J. Oglobine, 1998, British Journal of Cancer.

Exemestane as neoadjuvant hormonotherapy for locally advanced breast cancer: results of a phase II trial.

I. Bièche, G. MacGrogan, L. Mauriac, 2007, Anticancer research.

Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome

Urs Eppenberger, Mauro Delorenzi, Pratyaksha Wirapati, 2007, Breast Cancer Research.

Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis.

F. Spyratos, V. Le Doussal, K. Hacène, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Comparison of Enzyme Immunoassay and Immunohistochemical Measurements of Estrogen and Progesterone Receptors in Breast Cancer Patients

F. Spyratos, V. Le Doussal, M. Trassard, 2001, Applied immunohistochemistry & molecular morphology : AIMM.

Identification of potential prognostic biomarkers for node-negative breast tumours by proteomic analysis: a multicentric 2004 national PHRC study.

M. Campone, F. Spyratos, I. Zanella-Cléon, 2012, International journal of oncology.

CCND1 mRNA Overexpression is Highly Related to Estrogen Receptor Positivity but not to Proliferative Markers in Primary Breast Cancer

I. Bièche, M. Vidaud, R. Lidereau, 2000, The International journal of biological markers.

Prognostic value of uPA, PAI-1 and PAI-2 mRNA expression in primary breast cancer.

I. Bièche, V. Bécette, S. Tozlu, 2002, Anticancer research.

BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy

I. Bièche, B. Asselain, M. Marty, 2016, Breast Cancer Research and Treatment.

Immunohistochemistry of a component protein of the breast cystic disease fluid with mol. wt 15,000.

F. Spyratos, P. Franchimont, V. Le Doussal, 1985, European journal of cancer & clinical oncology.

Real-time reverse transcription PCR assay of CYP19 expression: application to a well-defined series of post-menopausal breast carcinomas

I. Bièche, S. Tozlu, I. Girault, 2002, The Journal of Steroid Biochemistry and Molecular Biology.

Expression analysis of mitotic spindle checkpoint genes in breast carcinoma: role of NDC80/HEC1 in early breast tumorigenicity, and a two-gene signature for aneuploidy

F. Lallemand, S. Vacher, I. Bièche, 2011, Molecular Cancer.

DNA and cell cycle analysis as prognostic indicators in breast tumors revisited.

G. Clark, P. Bendahl, C. B. Bagwell, 2001, Clinics in Laboratory Medicine.

Altered expression pattern of alternatively spliced estrogen receptor beta transcripts in breast carcinoma.

I. Bièche, S. Tozlu, I. Girault, 2004, Cancer letters.

ERBB2 status and benefit from adjuvant tamoxifen in ERalpha-positive postmenopausal breast carcinoma.

I. Bièche, M. Vidaud, S. Tozlu, 2001, Cancer letters.

PIK3R1 underexpression is an independent prognostic marker in breast cancer

S. Vacher, I. Bièche, R. Lidereau, 2013, BMC Cancer.

Prognostic value of estrogen and progesterone receptors in primary infiltrating ductal breast cancer. A sequential multivariate analysis of 1262 patients.

F. Spyratos, K. Hacène, C. Pallud, 1989, European journal of cancer & clinical oncology.

Cytologic nuclear grading of fine needle cytopunctures of breast carcinoma. Comparison with histologic nuclear grading and image cytometric data.

F. Spyratos, V. Le Doussal, M. Briffod, 1997, Analytical and quantitative cytology and histology.

Luteinizing hormone receptor status and clinical, pathologic, and prognostic features in patients with breast carcinomas

E. Milgrom, F. Spyratos, N. Charnaux, 2003, Cancer.

Immunomarker Studies of Fine‐Needle Cytopuncture Cell Blocks for Tumor Response Prediction After Preoperative Chemotherapy and Prognosis in Operable Nonmetastatic Primary Breast Carcinoma

V. Bécette, F. Spyratos, F. Lerebours, 2011, The breast journal.

DNA repair gene expression and risk of locoregional relapse in breast cancer patients.

S. Vacher, I. Bièche, R. Lidereau, 2010, International journal of radiation oncology, biology, physics.

[Quality control of the assay of receptors in human breast tumors].

E. Milgrom, F. Spyratos, M. Pichon, 1983, Pathologie-biologie.

Epidermal growth factor receptors and prognosis in primary breast cancer

R. Lidereau, F. Spyratos, M. Champème, 1990, Breast Cancer Research and Treatment.

Flow cytometric study of DNA distribution in cytopunctures of benign and malignant breast lesions.

F. Spyratos, A. Desplaces, M. Brunet, 1987, Analytical and quantitative cytology and histology.

Oligonucleotide microarray analysis of estrogen receptor alpha-positive postmenopausal breast carcinomas: identification of HRPAP20 and TIMELESS as outstanding candidate markers to predict the response to tamoxifen.

S. Vacher, I. Bièche, V. Lazar, 2007, Journal of molecular endocrinology.

Comparison of a new microplate oestrogen receptor (ER) enzyme immunoassay with other ER detection methods.

F. Spyratos, V. Le Doussal, L. Bellanger, 1997, British Journal of Cancer.

Quality control study by the French Cytometry Association on flow cytometric DNA content and S-phase fraction (S%). The Association Française de Cytométrie.

F. Spyratos, J. D'hautcourt, A. Chassevent, 1996, Cytometry.

The CGA gene as new predictor of the response to endocrine therapy in ERα-positive postmenopausal breast cancer patients

I. Bièche, M. Vidaud, R. Lidereau, 2001, Oncogene.

Menstrual status and breast cancer surgery

Y. Ville, F. Spyratos, K. Hacène, 1990, Breast Cancer Research and Treatment.

Tissue glycolytic enzymes in primary breast cancer patients receiving adjuvant chemotherapy.

R. Lidereau, F. Spyratos, A. Desplaces, 1986, European journal of cancer & clinical oncology.

Preoperative chemotherapy of operable breast cancer (stage IIIA). Prognostic factors of distant recurrence

F. Spyratos, K. Hacène, M. Briffod, 1993 .

Gynecological Cancers: A Challenge of Individualized Therapy in the Adjuvant and Palliative Setting

Quillien, I. Christensen, N. Harbeck, 2015 .

A Multicenter Randomized Phase II Study of Sequential Epirubicin/Cyclophosphamide Followed by Docetaxel with or without Celecoxib or Trastuzumab According to HER2 Status, as Primary Chemotherapy for Localized Invasive Breast Cancer Patient.

M. Mathieu, M. Marty, J. Pierga, 2009 .

Transcriptomic Profiles and Circulating Tumor Cell Detection in Primary Breast Cancer.

M. Espié, F. André, F. Reyal, 2009 .

Gene Transcript Assay by Real-Time Rt-PCR in Epithelial Breast Cancer Cells Selected by Laser Microdissection

I. Bièche, V. Bécette, F. Spyratos, 2004, The International journal of biological markers.

Prognostic value of a solubilized fraction of EGF receptors in primary breast cancer using an immunoenzymatic assay — a retrospective study

F. Spyratos, S. Romain, H. Magdelenat, 2004, Breast Cancer Research and Treatment.

Parathyroid hormone related protein (PTHrP) and breast cancer.

F. Spyratos, A. Jullienne, J. Guéris, 1991, Nouvelle revue francaise d'hematologie.

Prognostic of DNA‐synthesizing enzyme activities (thymidine kinase and thymidylate synthase) in 908 T1–T2, N0–N1, M0 breast cancers: A retrospective multicenter study

M. Bolla, F. Spyratos, S. Romain, 2000, International journal of cancer.